skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives

Review

(2667) Views  (843) Full article downloads

Authors: Madhuri Devabhaktuni, Sripal Bangalore

Published Date April 2009 Volume 2009:5 Pages 377 - 387
DOI: http://dx.doi.org/10.2147/VHRM.S3339

Madhuri Devabhaktuni1, Sripal Bangalore2

1Department of Medicine, Division of Cardiology, St Luke’s Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA; 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Abstract: Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition. Data have shown that even relatively small reductions in both blood pressure and cholesterol levels can lead to large reductions in the risk for cardiovascular events. However, though there are robust data on the beneficial effect of concomitant reduction in these risk factors, the reality is that this is achieved in ‹10% of patients. There is nonadherence with prescribed therapies with up to 50% of patients stopping their medications of their own volition for a variety of reasons. There is a reasonable evidence base to suggest that simplifying drug regimens and reducing pill burden will enhance patient adherence. The fixed-dose combination containing the antihypertensive agent amlodipine besylate and the statin atorvastatin is the first combination of its kind, which is both efficacious and safe and could potentially improve medication compliance, thereby improving the outcomes in these patients.

Keywords: amlodipine, atorvastatin, compliance, dyslipidemia, fixed-dose combination, hypertension








Readers of this article also read:

Prasugrel for the treatment of patients with acute coronary syndrome
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
MRI sagittal abdominal diameter is a stronger predictor of metabolic syndrome than visceral fat area or waist circumference in a high-risk vascular cohort
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University